# Efficacy and Safety Study of F373280

Study · id `cardio:ct-nct01831856` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01831856](<https://clinicaltrials.gov/study/NCT01831856>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01831856

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

## Technical summary

Registry record NCT01831856. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (actual); primary completion 2017-04-03 (actual). Results posted on 2019-07-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Started: 2013-04 (actual) (ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Primary completion: 2017-04-03 (actual) (ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Completion: 2017-06-21 (actual) (ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Results first posted: 2019-07-02 (ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Countries: Czechia; Hungary; Italy; Poland; Spain (ClinicalTrials.gov record NCT01831856, source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01831856-2019-07-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of F373280
- Condition: Atrial Fibrillation
- Intervention (Drug): 1g of F373280
- Intervention (Drug): Placebo
- Lead sponsor: Pierre Fabre Medicament
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 5db23fe6829d78306cfb84c60abfc080371d92b9b6a1129aa46b004cf30be168
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
